New Risk • Mar 19
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 26
Full year 2025 earnings released: EPS: NT$5.19 (vs NT$4.93 in FY 2024) Full year 2025 results: EPS: NT$5.19 (up from NT$4.93 in FY 2024). Revenue: NT$7.02b (up 3.4% from FY 2024). Net income: NT$927.7m (up 5.4% from FY 2024). Profit margin: 13% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 3% per year. Announcement • Feb 25
Standard Chemical & Pharmaceutical Co., Ltd., Annual General Meeting, May 12, 2026 Standard Chemical & Pharmaceutical Co., Ltd., Annual General Meeting, May 12, 2026, at 09:30 Taipei Standard Time. Location: no,154, k`ai yuan rd., sinying district, tainan city Taiwan Reported Earnings • Nov 12
Third quarter 2025 earnings released: EPS: NT$1.72 (vs NT$1.22 in 3Q 2024) Third quarter 2025 results: EPS: NT$1.72 (up from NT$1.22 in 3Q 2024). Revenue: NT$1.77b (up 1.6% from 3Q 2024). Net income: NT$307.6m (up 42% from 3Q 2024). Profit margin: 17% (up from 13% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 10% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 07
Second quarter 2025 earnings released: EPS: NT$1.10 (vs NT$1.21 in 2Q 2024) Second quarter 2025 results: EPS: NT$1.10 (down from NT$1.21 in 2Q 2024). Revenue: NT$1.83b (up 3.9% from 2Q 2024). Net income: NT$196.2m (down 9.1% from 2Q 2024). Profit margin: 11% (down from 12% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year. Upcoming Dividend • Jul 30
Upcoming dividend of NT$2.80 per share Eligible shareholders must have bought the stock before 06 August 2025. Payment date: 28 August 2025. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 4.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (2.6%). Declared Dividend • Jul 11
Dividend increased to NT$2.80 Dividend of NT$2.80 is 3.7% higher than last year. Ex-date: 6th August 2025 Payment date: 28th August 2025 Dividend yield will be 4.9%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 14% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • May 14
First quarter 2025 earnings released: EPS: NT$1.09 (vs NT$1.41 in 1Q 2024) First quarter 2025 results: EPS: NT$1.09 (down from NT$1.41 in 1Q 2024). Revenue: NT$1.64b (up 1.6% from 1Q 2024). Net income: NT$194.7m (down 23% from 1Q 2024). Profit margin: 12% (down from 16% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 01
Standard Chemical & Pharmaceutical Co. Ltd. to Report Q1, 2025 Results on May 09, 2025 Standard Chemical & Pharmaceutical Co. Ltd. announced that they will report Q1, 2025 results on May 09, 2025 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to NT$51.40, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 39% over the past three years. Announcement • Feb 26
Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, May 29, 2025 Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, May 29, 2025, at 09:00 Taipei Standard Time. Location: no,154, k`ai yuan rd., sinying district, tainan city Taiwan Announcement • Feb 18
Standard Chemical & Pharmaceutical Co. Ltd. to Report Fiscal Year 2024 Results on Feb 25, 2025 Standard Chemical & Pharmaceutical Co. Ltd. announced that they will report fiscal year 2024 results on Feb 25, 2025 Reported Earnings • Nov 15
Third quarter 2024 earnings released: EPS: NT$1.22 (vs NT$1.25 in 3Q 2023) Third quarter 2024 results: EPS: NT$1.22 (down from NT$1.25 in 3Q 2023). Revenue: NT$1.74b (up 5.9% from 3Q 2023). Net income: NT$217.4m (down 2.9% from 3Q 2023). Profit margin: 13% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 09
Second quarter 2024 earnings released: EPS: NT$1.21 (vs NT$1.33 in 2Q 2023) Second quarter 2024 results: EPS: NT$1.21 (down from NT$1.33 in 2Q 2023). Revenue: NT$1.76b (up 17% from 2Q 2023). Net income: NT$215.8m (down 9.5% from 2Q 2023). Profit margin: 12% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 30
Standard Chemical & Pharmaceutical Co. Ltd. to Report Q2, 2024 Results on Aug 06, 2024 Standard Chemical & Pharmaceutical Co. Ltd. announced that they will report Q2, 2024 results on Aug 06, 2024 Upcoming Dividend • Jul 27
Upcoming dividend of NT$2.70 per share Eligible shareholders must have bought the stock before 01 August 2024. Payment date: 30 August 2024. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of Taiwanese dividend payers (4.3%). Higher than average of industry peers (2.0%). Declared Dividend • Jul 10
Dividend of NT$2.70 announced Shareholders will receive a dividend of NT$2.70. Ex-date: 1st August 2024 Payment date: 30th August 2024 Dividend yield will be 3.7%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 18% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Board Change • Jul 09
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Chairman of the Board, President & GM Tzu-Ting Fan was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 10
First quarter 2024 earnings released: EPS: NT$1.41 (vs NT$1.18 in 1Q 2023) First quarter 2024 results: EPS: NT$1.41 (up from NT$1.18 in 1Q 2023). Revenue: NT$1.61b (up 8.1% from 1Q 2023). Net income: NT$252.7m (up 20% from 1Q 2023). Profit margin: 16% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 01
Standard Chemical & Pharmaceutical Co. Ltd. to Report Q1, 2024 Results on May 07, 2024 Standard Chemical & Pharmaceutical Co. Ltd. announced that they will report Q1, 2024 results on May 07, 2024 Reported Earnings • Mar 05
Full year 2023 earnings released: EPS: NT$4.67 (vs NT$4.56 in FY 2022) Full year 2023 results: EPS: NT$4.67 (up from NT$4.56 in FY 2022). Revenue: NT$6.24b (up 6.6% from FY 2022). Net income: NT$834.9m (up 2.4% from FY 2022). Profit margin: 13% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 28
Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024 Standard Chemical & Pharmaceutical Co. Ltd., Annual General Meeting, Jun 20, 2024. Location: 154 Kaiyuan Road, Sinying District, Tainan City 73055, Taiwan Tainan City Taiwan Agenda: To consider 2023 Business Report; to consider The 2023 Status of Shareholder Dividend Distribution Report; to consider Adoption of the 2023 Business Report and Financial Statements; and to transact such other business matters. Buy Or Sell Opportunity • Feb 26
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 3.8% to NT$68.60. The fair value is estimated to be NT$57.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 18%. Buy Or Sell Opportunity • Feb 16
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 10% to NT$68.50. The fair value is estimated to be NT$57.03, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 18%. Buy Or Sell Opportunity • Jan 22
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 6.3% to NT$63.80. The fair value is estimated to be NT$52.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 18%. Reported Earnings • Nov 14
Third quarter 2023 earnings released: EPS: NT$1.25 (vs NT$1.34 in 3Q 2022) Third quarter 2023 results: EPS: NT$1.25 (down from NT$1.34 in 3Q 2022). Revenue: NT$1.65b (up 6.2% from 3Q 2022). Net income: NT$223.9m (down 6.2% from 3Q 2022). Profit margin: 14% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 17% per year. Reported Earnings • Aug 10
Second quarter 2023 earnings released: EPS: NT$1.33 (vs NT$1.28 in 2Q 2022) Second quarter 2023 results: EPS: NT$1.33 (up from NT$1.28 in 2Q 2022). Revenue: NT$1.51b (up 1.9% from 2Q 2022). Net income: NT$238.3m (up 4.3% from 2Q 2022). Profit margin: 16% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 16% per year. Upcoming Dividend • Jul 27
Upcoming dividend of NT$2.50 per share at 3.8% yield Eligible shareholders must have bought the stock before 03 August 2023. Payment date: 31 August 2023. Payout ratio is a comfortable 52% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.5%). Higher than average of industry peers (1.4%). Valuation Update With 7 Day Price Move • Apr 18
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to NT$68.60, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 23x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 122% over the past three years. Reported Earnings • Mar 17
Full year 2022 earnings released: EPS: NT$4.56 (vs NT$3.96 in FY 2021) Full year 2022 results: EPS: NT$4.56 (up from NT$3.96 in FY 2021). Revenue: NT$5.85b (up 27% from FY 2021). Net income: NT$815.4m (up 15% from FY 2021). Profit margin: 14% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year whereas the company’s share price has increased by 22% per year. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improved over the past week After last week's 16% share price gain to NT$56.30, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 92% over the past three years. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Shaw-Tzong Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 06
Third quarter 2022 earnings released: EPS: NT$1.34 (vs NT$0.89 in 3Q 2021) Third quarter 2022 results: EPS: NT$1.34 (up from NT$0.89 in 3Q 2021). Revenue: NT$1.55b (up 38% from 3Q 2021). Net income: NT$238.6m (up 50% from 3Q 2021). Profit margin: 15% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Sep 06
Now 20% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be NT$59.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 25%. Buying Opportunity • Aug 18
Now 20% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be NT$59.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 25%. Reported Earnings • Aug 08
Second quarter 2022 earnings released: EPS: NT$1.28 (vs NT$0.93 in 2Q 2021) Second quarter 2022 results: EPS: NT$1.28 (up from NT$0.93 in 2Q 2021). Revenue: NT$1.48b (up 29% from 2Q 2021). Net income: NT$228.5m (up 38% from 2Q 2021). Profit margin: 15% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jul 21
Upcoming dividend of NT$2.50 per share Eligible shareholders must have bought the stock before 28 July 2022. Payment date: 24 August 2022. Payout ratio is a comfortable 67% and this is well supported by cash flows. Trailing yield: 5.5%. Lower than top quartile of Taiwanese dividend payers (6.7%). Higher than average of industry peers (2.9%). Reported Earnings • May 17
First quarter 2022 earnings released: EPS: NT$0.97 (vs NT$1.17 in 1Q 2021) First quarter 2022 results: EPS: NT$0.97 (down from NT$1.17 in 1Q 2021). Revenue: NT$1.24b (up 12% from 1Q 2021). Net income: NT$173.4m (down 17% from 1Q 2021). Profit margin: 14% (down from 19% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Shaw-Tzong Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 02
Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022 Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 21, 2022. Reported Earnings • Mar 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: NT$3.95 (up from NT$2.93 in FY 2020). Revenue: NT$4.60b (up 6.9% from FY 2020). Net income: NT$706.7m (up 35% from FY 2020). Profit margin: 15% (up from 12% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 12%, compared to a 9.0% growth forecast for the pharmaceuticals industry in Taiwan. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 07
Third quarter 2021 earnings released: EPS NT$0.89 (vs NT$0.64 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$1.12b (up 7.2% from 3Q 2020). Net income: NT$159.3m (up 40% from 3Q 2020). Profit margin: 14% (up from 11% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Board Change • Oct 12
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Shaw-Tzong Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 14
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Sep 13
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Sep 08
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Sep 07
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Sep 04
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 05
Second quarter 2021 earnings released: EPS NT$0.93 (vs NT$0.73 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: NT$1.15b (up 3.7% from 2Q 2020). Net income: NT$166.2m (up 28% from 2Q 2020). Profit margin: 14% (up from 12% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jul 22
Upcoming dividend of NT$1.80 per share Eligible shareholders must have bought the stock before 29 July 2021. Payment date: 25 August 2021. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (4.9%). Higher than average of industry peers (2.1%). Reported Earnings • May 06
First quarter 2021 earnings released: EPS NT$1.17 (vs NT$0.67 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$1.10b (up 6.4% from 1Q 2020). Net income: NT$208.3m (up 74% from 1Q 2020). Profit margin: 19% (up from 12% in 1Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 18
Full year 2020 earnings released: EPS NT$2.93 (vs NT$2.11 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$4.31b (up 9.4% from FY 2019). Net income: NT$524.2m (up 39% from FY 2019). Profit margin: 12% (up from 9.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Mar 17
Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 18, 2021 Standard Chem & Pharm CO., LTD., Annual General Meeting, Jun 18, 2021. Location: 154 Kaiyuan Road, Sinying District Tainan City Taiwan Agenda: To consider 2020 Business Report; to consider supervisors’ Review Report on the 2019 Financial Results; to consider 2020 Annual Report on Remuneration of Employees, Directors, and Supervisors; to consider the 2020 Status of Shareholder Dividend Distribution Report; to consider the 2020 Status of Endorsements and Guarantees; to consider the status of Implementation of Investments in Mainland China; to consider the reviewed report of the division, which prepared by the special committee of the M&A, between the company and SYN-TECH CHEM. & PHARM. Co., LTD.; to consider adoption of the 2020 Business Report and Financial Statements; to consider adoption of the Proposal for Distribution of 2020 Profits; to consider division Hecheng Dept. to SYN-TECH CHEM. & PHARM. Co by acquisition of the new shares of the company as the consideration; to consider amendment to the Company's Corporate Charter; and to consider other matters. Is New 90 Day High Low • Feb 01
New 90-day low: NT$35.20 The company is down 4.0% from its price of NT$36.70 on 03 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 17% over the same period. Is New 90 Day High Low • Jan 07
New 90-day low: NT$36.50 The company is down 6.0% from its price of NT$38.75 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 15% over the same period. Reported Earnings • Nov 05
Third quarter 2020 earnings released: EPS NT$0.64 The company reported a decent third quarter result with improved earnings, although revenues and profit margins were flat. Third quarter 2020 results: Revenue: NT$1.05b (flat on 3Q 2019). Net income: NT$114.2m (up 5.5% from 3Q 2019). Profit margin: 11% (in line with 3Q 2019). Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 5% per year. Is New 90 Day High Low • Oct 15
New 90-day low: NT$37.55 The company is down 14% from its price of NT$43.60 on 17 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Is New 90 Day High Low • Sep 29
New 90-day low: NT$37.70 The company is down 17% from its price of NT$45.55 on 01 July 2020. The Taiwanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. 
